Blog

Linkedin Facebook X-twitter Instagram Stem cell technologies are responsible for some of the most exciting areas of modern healthcare. A core element of this is the use of allogeneic stem cell therapy in regenerative medicine. These therapies use donor-derived somatic cells, which are dedifferentiated into induced pluripotent stem cells (iPSC). From here, iPSCs can be […]

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cell (iPSC)-based allogeneic cell therapies are set to transform many fields of healthcare, especially regenerative medicine1. These therapies mean that donor-derived iPSCs can be modified and scaled up for use as “off-the-shelf” treatments for neurodegenerative, cardiovascular, and retinal diseases, to name just a few. Automation is also emerging

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cells (iPSCs) are an incredibly powerful technology that continues to transform many facets of biomedicine. One particularly exciting area is the use of iPSC-derived cells as therapeutic agents. The development of allogeneic iPS cell-based therapies offers “off-the-shelf” therapies for regenerative medicine to treat conditions like cardiovascular disease, retinal degradation, and neurodegenerative

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cells (iPSCs) are revolutionizing biomedical research and healthcare by enabling the generation and modification of virtually any cell type to suit various applications. iPSCs are used for disease modeling, drug discovery, and personalized medicine, and the therapeutic potential of iPSCs is vast. Allogeneic cell therapies using iPSCs allow

Linkedin Facebook X-twitter Instagram Streamlining Monoclonal Antibody Production: From Quality Control to Cost Management Monoclonal antibody production is a critical process in modern medicine, supporting the development of therapeutics that have proven invaluable across oncology, immunology, and virology (Mekala et al., 2024). Ensuring high-quality and cost-effective production involves rigorous quality control, optimizing production workflows, and

Linkedin Facebook X-twitter Instagram Optimizing Your Monoclonal Antibody Production Workflow Monoclonal antibody production is a multi-step process that involves developing cell lines, optimizing culture conditions, and ensuring stringent quality control to produce consistent batches of high-quality, high-yield monoclonal antibodies. The production of monoclonal antibodies is crucial due to their therapeutic applications across cancer, immunology, and

Linkedin Facebook X-twitter Instagram Therapeutic Monoclonal Antibody Applications Monoclonal antibodies are highly specific antibodies designed to bind to a particular epitope on an antigen with high affinity (Castelli et al., 2019). Monoclonal antibodies are produced using hybridoma technology or Chinese Hamster Ovary (CHO) cells. Hybridoma technology was introduced by Köhler and Milstein in 1975 and

Linkedin Facebook X-twitter Instagram Hybridoma Technology: Quality Control and Best Practices Hybridoma technology was first described in 1975 by Georges Köhler and Cesar Milstein, who were jointly awarded the Nobel Prize in Physiology or Medicine in 1984 for their discovery (Köhler & Milstein, 1975; The Nobel Prize in Physiology or Medicine 1984, n.d.). It enables

Linkedin Facebook X-twitter Instagram Cell Line Development: Comprehensive Insights and Advances Cell line development is a cornerstone of several modern biomedical applications. It provides essential models for studying diseases and tools for developing the latest therapeutic products1. Researchers leverage the unique benefits of mammalian cell lines and innovations in gene editing, such as clustered regularly

Linkedin Facebook X-twitter Instagram Maximizing Efficiency in Cell Line Development: Techniques and Tips Cell line development is essential for producing many modern therapies, including complex molecules and cell-based therapies1. New automation and genetic engineering technologies have made cell line development increasingly competitive. This acceleration in capabilities allows companies to bring novel therapeutics to market more

Linkedin Facebook X-twitter Instagram Gene Editing in Cell Line Development: Cutting-Edge Approaches Advances in gene editing have revolutionized biomedical research and cell line development. New techniques are changing how we approach drug discovery and therapy production, from enhancing the stability and productivity of monoclonal cell lines to creating precise disease models1. Techniques like clustered regularly

Linkedin Facebook X-twitter Instagram Introducing the CYTENA Cell and Gene Therapy Tracker Our clients are breaking new ground in cell and gene therapies, and we wanted to create an easy way to keep tabs on what this community is up to. That’s why we created a tool to track the current pipeline of cell and